{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:54Z","timestamp":1789584894469,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) demonstrating liver-dominant inoperable metastatic diseases or locally advanced inoperable tumors may at times show reduced efficacy for intravenous peptide receptor radionuclide therapy (PRRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims and objectives<\/jats:title>\n                    <jats:p>\n                      To determine and compare the outcome of intra-arterial [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE PRRT in GEP-NET with locally advanced inoperable primary or liver-dominant metastases who had shown no response after at least two cycles of intravenous [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE, as compared to those patients who continued intravenous [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE only.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      GEP-NET patients with locally advanced inoperable primary or liver metastatic disease, who exhibited nonresponsive disease (either stable or progressive disease on anatomical imaging evaluation) after at least two cycles of intravenous [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE PRRT, were administered intra-arterial [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE PRRT (group A). For comparison, matched controls [age, gender, primary site, tumor grade, proliferation index, disease burden, and [\n                      <jats:sup>18<\/jats:sup>\n                      F]fluorodeoxyglucose (FDG) PET\/computed tomography status] who had received only intravenous [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE PRRT (group B) were selected retrospectively. The data were compared and analyzed for response assessments across three categories (symptomatic, including various quality-of-life scores; biochemical; and imaging), survival outcomes, and toxicity profiles.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 33 GEP-NET patients (group A-11 and group B-22) were included. Symptomatic alleviation was slightly higher in group A compared with group B (75 vs. 66.8%), with higher quality-of-life (QoL) scores in group A. According to RECIST 1.1, group A had a 36.3% objective response rate compared with 13.6% in group B. Group A had a higher disease control rate (90.8%) than group B (77.2%). The median progression-free survival (PFS) was significantly longer in group A (not attained) compared with group B (median PFS of 22 months;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). No major toxicity was observed in either group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Intra-arterial [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE resulted in a higher response rate, symptomatic relief, improved QoL, and prolonged PFS in patients whose disease remained nonresponsive after intravenous [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE. Prospective randomized controlled trials can further validate the incorporation of intra-arterial PRRT into the management of GEP-NETs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002173","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T08:00:07Z","timestamp":1779436807000},"page":"1029-1040","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of intra-arterial [177Lu]Lu-DOTATATE vs. continuation intravenous [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy in nonresponding locally advanced inoperable or liver-dominant metastatic gastroenteropancreatic neuroendocrine tumors"],"prefix":"10.1097","volume":"47","author":[{"given":"Rangat","family":"Bagasariya","sequence":"first","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe"},{"name":"Homi Bhabha National Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul Vithalrao","family":"Parghane","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe"},{"name":"Homi Bhabha National Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Shetty","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute"},{"name":"Department of Radiology, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Gala","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute"},{"name":"Department of Radiology, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyash","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute"},{"name":"Department of Radiology, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6607-2558","authenticated-orcid":false,"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe"},{"name":"Homi Bhabha National Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080731","article-title":"Epidemiology of neuroendocrine tumours.","volume":"80","author":"Taal","year":"2004","journal-title":"Neuroendocrinology"},{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u2018carcinoid\u2019: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]Octreotate: toxicity, efficacy, and survival.","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.113.125336","article-title":"Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.","volume":"55","author":"Ezziddin","year":"2014","journal-title":"J Nucl Med"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors.","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","article-title":"Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.","volume":"47","author":"Strosberg","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors.","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors.","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","article-title":"Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours.","volume":"41","author":"Ezziddin","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"20201041","DOI":"10.1259\/bjr.20201041","article-title":"Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with metastatic advanced neuroendocrine tumours: a single institutional observation in a large tertiary care setting.","volume":"94","author":"Sitani","year":"2021","journal-title":"Br J Radiol"},{"key":"R12-20260805","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00259-019-04499-x","article-title":"Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.","volume":"47","author":"Adant","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-0043-1778658","article-title":"Intra-arterial peptide receptor radionuclide therapy for the treatment of hepatic neuroendocrine tumor metastases: hope or hype?","volume":"41","author":"Khanjyan","year":"2024","journal-title":"Semin Intervent Radiol"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00259-023-06467-y","article-title":"Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA).","volume":"51","author":"Ebbers","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20260805","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/jcm10081794","article-title":"Radiological and clinical efficacy of intra-arterial 90Y-DOTATATE in patients with unresectable, progressive, liver-dominant neuroendocrine neoplasms.","volume":"10","author":"Kolasi\u0144ska-\u0106wik\u0142a","year":"2021","journal-title":"J Clin Med"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:00:17Z","timestamp":1785920417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002173","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"2026-02-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}